July 18, 2025: Meeting of the Psychopharmacologic Drugs Advisory Committee Meeting Announcement – 07/18/2025

Caspofungin Injection

Drug Trials Snapshots: VIZZ

FDA’s surrogate endpoint table provides valuable information for drug developers on endpoints that may be considered and discussed with FDA for individual development programs.

These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion’s untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.

The FDA granted supplemental approval to Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. This is the first FDA-approved treatment option for this indication.

The Food and Drug Administration is advising consumers not to purchase or use VITAFER-L Gold 10ml, a product promoted for energy and sexual enhancement on various websites, including www.amazon.com.